AnaptysBio (NASDAQ:ANAB) CEO Daniel Faga Sells 9,202 Shares

AnaptysBio, Inc. (NASDAQ:ANAB) CEO Daniel Faga sold 9,202 shares of AnaptysBio stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $45.11, for a total value of $415,102.22. Following the transaction, the chief executive officer directly owned 466,787 shares in the company, valued at approximately $21,056,761.57. The trade was a 1.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Daniel Faga also recently made the following trade(s):

• On Monday, January 5th, Daniel Faga sold 15,309 shares of AnaptysBio stock. The shares were sold at an average price of $43.26, for a total value of $662,267.34.

AnaptysBio Price Performance

ANAB opened at $43.80 on Friday. AnaptysBio, Inc. has a 1 year low of $12.21 and a 1 year high of $52.47. The company has a market capitalization of $1.21 billion, a price-to-earnings ratio of -15.53 and a beta of 0.32. The firm’s fifty day moving average price is $42.46 and its two-hundred day moving average price is $31.30.

AnaptysBio (NASDAQ:ANAB) last announced its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 EPS for the quarter, beating the consensus estimate of ($1.06) by $1.58. AnaptysBio had a negative net margin of 49.94% and a negative return on equity of 1,101.24%. The company had revenue of $76.32 million during the quarter, compared to the consensus estimate of $15.83 million. As a group, equities analysts anticipate that AnaptysBio, Inc. will post -6.08 EPS for the current year.

AnaptysBio declared that its board has approved a stock buyback program on Friday, November 21st that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the biotechnology company to reacquire up to 9.6% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Analyst Ratings Changes

A number of analysts recently commented on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. Wells Fargo & Company lifted their target price on AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 5th. HC Wainwright cut their price target on shares of AnaptysBio from $52.00 to $51.00 and set a “buy” rating on the stock in a report on Monday, November 24th. Barclays decreased their price objective on shares of AnaptysBio from $70.00 to $55.00 and set an “overweight” rating for the company in a report on Wednesday, December 17th. Finally, Stifel Nicolaus dropped their target price on shares of AnaptysBio from $80.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, December 11th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, AnaptysBio has a consensus rating of “Moderate Buy” and a consensus price target of $60.40.

More AnaptysBio News

Here are the key news stories impacting AnaptysBio this week:

• Positive Sentiment: UBS upgraded AnaptysBio to a “strong‑buy,” which can drive retail and institutional buying interest and lift short‑term momentum. UBS upgrade / coverage note
• Positive Sentiment: AnaptysBio filed a partial motion to dismiss Tesaro/GSK’s anticipatory‑breach claim related to Jemperli royalties; a successful dismissal would reduce legal and royalty exposure and improve free‑cash‑flow prospects tied to that program. AnaptysBio seeks partial dismissal in GSK dispute
• Negative Sentiment: CEO Daniel Faga sold about $662k of stock (9,202 shares), a disclosed insider sale that can raise investor concerns about insider conviction even though his remaining stake is still large. CEO stock sale article
• Negative Sentiment: Other insiders (CFO Dennis Mulroy, Paul Lizzul, Eric Loumeau and others) also sold shares in the same filing period — several sizable dispositions that increase selling pressure and may temper the upside from analyst upgrades or legal wins. SEC Form 4 filings detail these trades. SEC Form 4 filings (insider sales)

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. AQR Capital Management LLC grew its position in shares of AnaptysBio by 153.3% in the first quarter. AQR Capital Management LLC now owns 30,011 shares of the biotechnology company’s stock valued at $558,000 after purchasing an additional 18,165 shares in the last quarter. Woodline Partners LP increased its position in shares of AnaptysBio by 63.1% during the first quarter. Woodline Partners LP now owns 791,023 shares of the biotechnology company’s stock valued at $14,705,000 after buying an additional 305,950 shares during the period. Rhumbline Advisers lifted its holdings in shares of AnaptysBio by 2.7% in the first quarter. Rhumbline Advisers now owns 30,903 shares of the biotechnology company’s stock worth $574,000 after buying an additional 826 shares in the last quarter. Voya Investment Management LLC bought a new position in shares of AnaptysBio in the first quarter valued at approximately $1,803,000. Finally, HighMark Wealth Management LLC increased its holdings in shares of AnaptysBio by 58.2% in the second quarter. HighMark Wealth Management LLC now owns 145,550 shares of the biotechnology company’s stock worth $3,231,000 after purchasing an additional 53,550 shares during the period.

AnaptysBio Company Profile

AnaptysBio, Inc is a clinical-stage biotechnology company focused on the discovery and development of therapeutic antibody product candidates in immunology and inflammation. Founded in 2012 and headquartered in San Diego, California, AnaptysBio leverages a proprietary somatic hypermutation platform to rapidly generate and refine human antibodies with optimized efficacy and safety profiles. The company’s technology is designed to accelerate target validation and candidate selection across a range of immune-mediated conditions.

The company’s pipeline includes multiple clinical-stage programs addressing dermatological and inflammatory disorders.